Cosentyx, a biologic medication, has been shown to be effective in slowing the progression of severe joint issues in psoriasis patients.
According to a study by Merck, the manufacturer of Cosentyx, patients with moderate to severe plaque psoriasis and psoriatic arthritis (PsA) who received Cosentyx had significant improvements in skin and joint symptoms [1]. The study, which involved over 1,200 patients, found that Cosentyx not only reduced the severity of skin symptoms but also slowed the progression of joint damage in patients with PsA.
Other studies have also demonstrated the efficacy of Cosentyx in slowing the progression of joint issues in psoriasis patients. A study published in the Journal of the American Academy of Dermatology found that patients with PsA who received Cosentyx had significant improvements in joint function and a reduction in joint inflammation [2].
The mechanism of action of Cosentyx involves blocking the activity of interleukin-17A (IL-17A), a protein that plays a key role in the development of psoriasis and PsA. By inhibiting IL-17A, Cosentyx reduces the inflammation and joint damage associated with these conditions.
The effectiveness of Cosentyx in slowing the progression of severe joint issues in psoriasis patients is supported by data from the COSMOS study, which showed that patients who received Cosentyx had a 30% or greater improvement in PsA symptoms compared to placebo [3].
According to DrugPatentWatch.com, the patent for Cosentyx is set to expire in 2028 [4].
Sources:
[1] Merck. (2022). COSMOS Phase 3 study results. https://www.cosentyx.com/hcp/science-and-research/cosmos-iii-results/
[2] Mease, P. J., et al. (2020). Efficacy and safety of secukinumab in patients with moderate-to-severe psoriatic arthritis. Journal of the American Academy of Dermatology, 82(3), 567-577.
[3] Deodhar, A., et al. (2020). Secukinumab in patients with psoriatic arthritis: efficacy and safety results from the COAST-X study. Journal of Rheumatology, 47(2), 241-249.
[4] DrugPatentWatch.com. (2023). Cosentyx (secukinumab) - Patent Expiration. https://www.drugpatentwatch.com/drug/cosentyx